Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases

Şenel, Sevda; Yüksel, Selin

doi:10.1007/s13346-020-00806-4

Cited by 21 publications

(6 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its biocompatibility, biodegradability, nontoxicity, mucoadhesivity, and hemocompatibility are ideal characteristics for designing nanocarriers with controlled delivery and sustained release of various therapeutics [10,[20][21][22][23][24][25][26][27]. Chitosan has shown great promise in nanodelivery for the treatment of cancer [28][29][30], diabetes [31][32][33], eye diseases [34][35][36], infectious diseases [37][38][39][40][41], and more, being also recently employed in the delivery of vaccines [42][43][44][45].…”

Section: Individual and Synergic Propertiesmentioning

confidence: 99%

Applications of Chitosan-Alginate-Based Nanoparticles—An Up-to-Date Review

2022

View full text Add to dashboard Cite

Chitosan and alginate are two of the most studied natural polymers that have attracted interest for multiple uses in their nano form. The biomedical field is one of the domains benefiting the most from the development of nanotechnology, as increasing research interest has been oriented to developing chitosan-alginate biocompatible delivery vehicles, antimicrobial agents, and vaccine adjuvants. Moreover, these nanomaterials of natural origin have also become appealing for environmental protection (e.g., water treatment, environmental-friendly fertilizers, herbicides, and pesticides) and the food industry. In this respect, the present paper aims to discuss some of the newest applications of chitosan-alginate-based nanomaterials and serve as an inception point for further research in the field.

show abstract

Section: Individual and Synergic Propertiesmentioning

confidence: 99%

Applications of Chitosan-Alginate-Based Nanoparticles—An Up-to-Date Review

2022

View full text Add to dashboard Cite

show abstract

“…Since the fusion of viral membrane with host cell membrane is mediated by S2 subunit of S glycoprotein, it is likely that the interaction of chitosan and derived chitosan molecules with S2 subunit interferes with the fusion events, thus reducing incorporation of viral RNA into host cells ( Table 1 ). Chitosan and related chitosan molecules are widely used as drugs for different therapeutic applications such as particulate systems for drug and vaccine delivery ( 79 ). These molecules are also used in tissue engineering as extracellular matrix because they are innocuous, non-immunogenic, and non-toxic ( 80 ).…”

Section: Glycobiological Human Defense To Sars-cov-2 Infectionmentioning

confidence: 99%

How glycobiology can help us treat and beat the COVID-19 pandemic

Lardone¹,

Garay²,

Parodi³

et al. 2021

Journal of Biological Chemistry

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerge during the last months of 2019, expanding throughout the world as a highly transmissible infectious illness designated as COVID-19. Vaccines have now appeared, but the challenges in producing sufficient material and distributing them around the world means that effective treatments to limit infection and improve recovery are still urgently needed. This review is focused on the relevance of different glycobiological molecules that could potentially serve as or inspire therapeutic tools during SARS-CoV-2 infection. As such, we highlight the glycobiology of the SARS-CoV-2 infection process, where glycans on viral proteins and on host glycosaminoglycans have critical roles in efficient infection. We also take notice of the glycan-binding proteins involved in the infective capacity of virus and in human defense. In addition, we critically evaluate the glycobiological contribution of candidate drugs for COVID-19 therapy such as glycans for vaccines, anti-glycan antibodies, recombinant lectins, lectin inhibitors, glycosidase inhibitors, polysaccharides, and numerous glycosides, emphasizing some opportunities to repurpose FDA-approved drugs. For the next generation drugs suggested here, biotechnological engineering making new probes to block the SARS-CoV-2 infection might be based in the essential glycobiological insight on glycosyltransferases, glycans, glycan-binding proteins and glycosidases related to this pathology.

show abstract

“…In addition, chitosan, a cationic polysaccharide of natural origin, has been recently indicated as one of the most promising excipients for veterinary applications ( 10 – 12 ). Chitosan presents a series of appealing properties as nasal and vaccine excipient, providing mucoadhesion, enhanced mucosal permeability, control of the antigen release and adjuvant effects ( 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Nano-adjuvanted dry powder vaccine for the mucosal immunization against airways pathogens

et al. 2023

View full text Add to dashboard Cite

Nasal vaccination has been shown to provide optimal protection against respiratory pathogens. However, mucosal vaccination requires the implementation of specific immunization strategies to improve its effectiveness. Nanotechnology appears a key approach to improve the effectiveness of mucosal vaccines, since several nanomaterials provide mucoadhesion, enhance mucosal permeability, control antigen release and possess adjuvant properties. Mycoplasma hyopneumoniae is the main causative agent of enzootic pneumonia in pigs, a respiratory disease responsible for considerable economic losses in the pig farming worldwide. The present work developed, characterized, and tested in vivo an innovative dry powder nasal vaccine, obtained from the deposition on a solid carrier of an inactivated antigen and a chitosan-coated nanoemulsion, as an adjuvant. The nanoemulsion was obtained through a low-energy emulsification technique, a method that allowed to achieve nano droplets in the order of 200 nm. The oil phase selected was alpha-tocopherol, sunflower oil, and poly(ethylene glycol) hydroxystearate used as non-ionic tensioactive. The aqueous phase contained chitosan, which provides a positive charge to the emulsion, conferring mucoadhesive properties and favoring interactions with inactivated M. hyopneumoniae. Finally, the nanoemulsion was layered with a mild and scalable process onto a suitable solid carrier (i.e., lactose, mannitol, or calcium carbonate) to be transformed into a solid dosage form for administration as dry powder. In the experimental study, the nasal vaccine formulation with calcium carbonate was administered to piglets and compared to intramuscular administration of a commercial vaccine and of the dry powder without antigen, aimed at evaluating the ability of IN vaccination to elicit an in vivo local immune response and a systemic immune response. Intranasal vaccination was characterized by a significantly higher immune response in the nasal mucosa at 7 days post-vaccination, elicited comparable levels of Mycoplasma-specific IFN-γ secreting cells and comparable, if not higher, responsiveness of B cells expressing IgA and IgG in peripheral blood mononuclear cells, with those detected upon a conventional intramuscular immunization. In conclusion, this study illustrates a simple and effective strategy for the development of a dry powder vaccine formulation for nasal administration which could be used as alternative to current parenteral commercial vaccines.

show abstract

Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases

Cited by 21 publications

References 167 publications

Applications of Chitosan-Alginate-Based Nanoparticles—An Up-to-Date Review

Applications of Chitosan-Alginate-Based Nanoparticles—An Up-to-Date Review

How glycobiology can help us treat and beat the COVID-19 pandemic

Nano-adjuvanted dry powder vaccine for the mucosal immunization against airways pathogens

Contact Info

Product

Resources

About